Back to Authors

Stander, Zinandré

Mayo Clinic

Mayo Clinic

Citations 2

MT‐ATP6 mitochondrial disease identified by newborn screening reveals a distinct biochemical phenotype
Tise, Christina G. , Verscaj, Courtney P. , Mendelsohn, Bryce A. , Woods, Jeremy D. , Lee, Chung U. , Enns, Gregory M. , Stander, Zinandré, Cowan, Tina M. , Cusmano‐Ozog, Kristina , Hall, Patricia

American Journal of Medical Genetics Part A | March 8, 2023 | Volume: 191 | Issue: 6 | Pages: 1492-1501

10.1002/ajmg.a.63159 Get It

AbstractAlthough decreased citrulline is used as a newborn screening (NBS) marker to identify proximal urea cycle disorders (UCDs), it is also a feature of some mitochondrial diseases, including MT‐ATP6 mitochondrial disease. Here we describe biochemical and clinical features of 11 children born to eight mothers from seven separate families who were identified with low citrulline by NBS (range 3–5 μM; screening cutoff >5) and ultimately diagnosed with MT‐ATP6 mitochondrial disease. Follow‐up testing revealed a pattern of hypocitrullinemia together with elevated propionyl‐(C3) and 3‐hydroxyisovaleryl‐(C5‐OH) acylcarnitines, and a homoplasmic pathogenic variant in MT‐ATP6 in all cases. Single and multivariate analysis of NBS data from the 11 cases using Collaborative Laboratory Integrated Reports (CLIR; https://clir.mayo.edu) demonstrated citrulline <1st percentile, C3 > 50th percentile, and C5‐OH >90th percentile when compared with reference data, as well as unequivocal separation from proximal UCD cases and false‐positive low citrulline cases using dual scatter plots. Five of the eight mothers were symptomatic at the time of their child(ren)'s diagnosis, and all mothers and maternal grandmothers evaluated molecularly and biochemically had a homoplasmic pathogenic variant in MT‐ATP6, low citrulline, elevated C3, and/or elevated C5‐OH. All molecularly confirmed individuals (n = 17) with either no symptoms (n = 12), migraines (n = 1), or a neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) phenotype (n = 3) were found to have an A or U mitochondrial haplogroup, while one child with infantile‐lethal Leigh syndrome had a B haplogroup.
Progressive brain atrophy and severe neurodevelopmental phenotype in siblings with biallelic COASY variants
Rosati, Justin , Johnson, Jessica, Stander, Zinandré, White, Amy , Tortorelli, Silvia , Bailey, Diana, Fong, Chin‐To, Lee, Bo Hoon , White, Amy L , Lee, Bo Hoon

American Journal of Medical Genetics Part A | December 10, 2022 | Volume: 191 | Issue: 3 | Pages: 842-845

10.1002/ajmg.a.63076 Get It

Abstract Biallelic pathogenic variants in the COASY gene have been associated with two distinct disease phenotypes, that is, COASY ‐protein associated neurodegeneration (CoPAN) and pontocerebellar hypoplasia type 12 (PCH 12). We present two siblings that independently presented with significant hypotonia and respiratory insufficiency at birth. Comprehensive genetic testing revealed homozygous variants within COASY , however, the progressive clinical and neuroradiologic findings described here are unique and have not been described previously. Magnetic resonance imaging showed progressive diffuse parenchymal loss throughout the bilateral cerebral hemispheres and atrophy of the basal ganglia and brainstem. As such, this article brings forth two additional cases of COASY ‐related disorder with abnormal newborn screening acylcarnitine profiles resembling carnitine palmitoyl transferase 1a (CPT1a) deficiency in two siblings who presented at birth with contractures, marked hypotonia and absent respiratory drive.